2763378-71-6
Chemical Structure
JW-65
- CAS No.: 2763378-71-6
- Formula:C18H13Cl2F3N4O2
- Molecular Weight:445.22
IUPAC Name: 1-(4-(3,4-dichloro-2-oxopyridin-1(2H)-yl)phenyl)-N-ethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
InChIKey: ZTDUAAMBQLCQSR-UHFFFAOYSA-N
SMILES: FC(C1=C(C(NCC)=O)C=NN1C2=CC=C(C=C2)N(C=CC(Cl)=C3Cl)C3=O)(F)F
Biological Activity: JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JW-65 | 99.05% | JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Silva-Cardoso GK, et al. Inhibition of TRPC3 channels suppresses seizure susceptibility in the genetically-epilepsy prone rats. Eur J Pharmacol. 2024;977:176722. [Content Brief]
- [2]. Zhang S, et al. Discovery of a Highly Selective and Potent TRPC3 Inhibitor with High Metabolic Stability and Low Toxicity. ACS Med Chem Lett. 2021;12(4):572-578. Published 2021 Mar 5. [Content Brief]
- [3]. Nagib MM, et al. Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects. Epilepsia. 2022;63(4):1003-1015. [Content Brief]
